Monitoring Protocols for Cochlear Toxicity

Abstract The need for monitoring hearing and auditory function during drug therapy and other treatments that have the potential to cause hearing loss is well documented. Besides the main purpose of ototoxic monitoring, which is to provide feedback to the attending physician about the effects the treatment is having on the auditory system, it is also helpful in setting expectations for the patient and his/her family about the communication issues that may result from the drug therapy. This article will review tests available to an audiologist, both subjective and objective, that can be used to effectively monitor hearing levels and auditory function during treatment. Published guidelines and various ototoxic monitoring protocols are reviewed regarding tests administered, what constitutes a significant change in test results and how these findings are reported, and the impact significant changes may have on the course of treatment. Test protocols from different institutions are compared for both similarities and contrasts. Effective scheduling and test location are key to a successful monitoring program. Finally, the need to streamline ototoxic monitoring of hearing and auditory function to reduce test time and make it less stressful and tiresome on the patient will be considered.

[1]  Lisa L. Hunter,et al.  Evaluation of Speed and Accuracy of Next-Generation Auditory Steady State Response and Auditory Brainstem Response Audiometry in Children With Normal Hearing and Hearing Loss , 2018, Ear and hearing.

[2]  K. Knight,et al.  Ototoxicity monitoring in children treated with platinum chemotherapy , 2018, International journal of audiology.

[3]  C. McEvoy,et al.  Monitoring neonates for ototoxicity , 2018, International journal of audiology.

[4]  D. Konrad-Martin,et al.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions , 2018, International journal of audiology.

[5]  D. Konrad-Martin,et al.  Ototoxicity monitoring through the eyes of the treating physician: Perspectives from pulmonology and medical oncology , 2018, International journal of audiology.

[6]  Tanisha L. Hammill,et al.  Protection for medication-induced hearing loss: the state of the science , 2018, International journal of audiology.

[7]  V. Manchaiah,et al.  Ototoxicity: A Challenge in Diagnosis and Treatment , 2018, Journal of audiology & otology.

[8]  A. Boothroyd,et al.  High-Frequency Distortion-Product Otoacoustic Emission Repeatability in a Patient Population , 2017, Ear and hearing.

[9]  G. McMillan,et al.  Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring , 2017, Ear and hearing.

[10]  B. Gál,et al.  Genetic risk factors of cisplatin induced ototoxicity in adult patients. , 2016, Neoplasma.

[11]  W. Dreschler,et al.  Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literature , 2015, Head & neck.

[12]  Shaum P. Bhagat,et al.  Challenges in ototoxicity monitoring in the pediatric oncology population. , 2014, Journal of the American Academy of Audiology.

[13]  G. McMillan,et al.  Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). , 2014, Journal of rehabilitation research and development.

[14]  P. Steyger,et al.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Fausti,et al.  Ototoxicity Monitoring: Program Approaches and Considerations , 2011 .

[16]  Frederick J. Gallun,et al.  Distortion-Product Otoacoustic Emission Test Performance for Ototoxicity Monitoring , 2010, Ear and hearing.

[17]  A. Grimes,et al.  American Academy of Audiology Position Statement , 2010 .

[18]  S. Fausti,et al.  Factors Affecting Sensitivity of Distortion-Product Otoacoustic Emissions to Ototoxic Hearing Loss , 2008, Ear and hearing.

[19]  K. Knight,et al.  Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Fausti,et al.  Audiological Monitoring of Patients Receiving Ototoxic Drugs , 2005 .

[21]  S. Fausti,et al.  Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. , 2005, Journal of rehabilitation research and development.

[22]  N. Fischel‐Ghodsian Genetic Factors in Aminoglycoside Toxicity , 1999, Pharmacogenomics.

[23]  Alison M. Bobal,et al.  Comparison of ABR stimuli for the early detection of ototoxicity: conventional clicks compared with high frequency clicks and single frequency tonebursts. , 2003, Journal of the American Academy of Audiology.

[24]  R. Santarelli,et al.  Global Problem of Drug‐Induced Hearing Loss , 1999, Annals of the New York Academy of Sciences.

[25]  M P Gorga,et al.  Comparison between intensity and pressure as measures of sound level in the ear canal. , 1998, The Journal of the Acoustical Society of America.

[26]  S. Neely,et al.  From Laboratory to Clinic: A Large Scale Study of Distortion Product Otoacoustic Emissions in Ears with Normal Hearing and Ears with Hearing Loss , 1997, Ear and hearing.

[27]  R H Wilson,et al.  High‐Frequency Audiometric Monitoring Strategies for Early Detection of Ototoxicity , 1994, Ear and hearing.

[28]  J. Durrant,et al.  Audiologic monitoring for ototoxicity. , 1993, Otolaryngologic clinics of North America.

[29]  J. Johnson,et al.  Hearing loss--risk factor for cisplatin ototoxicity? Observations. , 1990, The American journal of otology.

[30]  G. Studebaker,et al.  Placement of vibrator in bone-conduction testing. , 1962, Journal of speech and hearing research.